Evidence map›Paper›PMID 36551795›Full record

ArticleBiomedicines2022

Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs.

Valentina Mazziotti, Francesco Crescenzo, Agnese Tamanti, Caterina Dapor, Stefano Ziccardi, Maddalena Guandalini, Annalisa Colombi, Valentina Camera, Angela Peloso, Francesco Pezzini and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Valentina MazziottiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-8746-1082
Francesco CrescenzoNeurology Unit, "Mater Salutis" Hospital, ULSS 9 Scaligera, 37045 Legnago, Italy.ORCID 0000-0003-1396-7774
Agnese TamantiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Caterina DaporDepartment of General Psychology, University of Padova, 35131 Padua, Italy.ORCID 0000-0001-5121-818X
Stefano ZiccardiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0003-0426-7223
Maddalena GuandaliniDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0003-2341-9253
Annalisa ColombiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Valentina CameraDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Angela PelosoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Francesco PezziniDepartment of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, 37134 Verona, Italy.ORCID 0000-0003-1590-4558
Ermanna TuranoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-0760-1787
Damiano MarastoniDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Massimiliano CalabreseDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-3362-7403
University of Verona · ITUniversity of Padua · IT

Funding

International Progressive MS Alliance (Progressive MS Alliance) PA-2002-36191
6 · The paper itself

Abstract

The impact of disease-modifying therapies (DMTs) on the immune response to coronavirus disease-2019 (COVID-19) vaccines in persons with multiple sclerosis (pwMS) needs further elucidation. We investigated BNT162b2 mRNA COVID-19 vaccine effects concerning antibody seroconversion, inflammatory mediators' level and immunophenotype assessment in pwMS treated with cladribine (c-pwMS,

Indexed as

cellular immune responseCOVID-19disease-modifying therapiesimmunophenotypeinflammatory mediatorsmultiple sclerosisseroconversionvaccination

Identifiers

PMID36551795
PMCPMC9775192
OpenAlexW4309938068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.